These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 15102606)
41. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. Calarota SA; Kjerrström A; Islam KB; Wahren B Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166 [TBL] [Abstract][Full Text] [Related]
42. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. Berinstein NL J Clin Oncol; 2002 Apr; 20(8):2197-207. PubMed ID: 11956282 [TBL] [Abstract][Full Text] [Related]
43. Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes. Bissa M; Forlani G; Zanotto C; Tosi G; De Giuli Morghen C; Accolla RS; Radaelli A PLoS One; 2018; 13(1):e0190869. PubMed ID: 29385169 [TBL] [Abstract][Full Text] [Related]
44. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. Engelmayer J; Larsson M; Lee A; Lee M; Cox WI; Steinman RM; Bhardwaj N J Virol; 2001 Mar; 75(5):2142-53. PubMed ID: 11160718 [TBL] [Abstract][Full Text] [Related]
45. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. Dullaers M; Thielemans K J Gene Med; 2006 Jan; 8(1):3-17. PubMed ID: 16288497 [TBL] [Abstract][Full Text] [Related]
53. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2). Acres B J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281 [TBL] [Abstract][Full Text] [Related]
54. Recombinant vectors as influenza vaccines. Kopecky-Bromberg SA; Palese P Curr Top Microbiol Immunol; 2009; 333():243-67. PubMed ID: 19768410 [TBL] [Abstract][Full Text] [Related]
55. A review of dendritic cell therapy for cancer: progress and challenges. Mantia-Smaldone GM; Chu CS BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406 [TBL] [Abstract][Full Text] [Related]
56. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. Chen X; Rock MT; Hammonds J; Tartaglia J; Shintani A; Currier J; Slike B; Crowe JE; Marovich M; Spearman P J Virol; 2005 May; 79(9):5537-47. PubMed ID: 15827168 [TBL] [Abstract][Full Text] [Related]
57. A therapeutic HIV vaccine using coxsackie-HIV recombinants: a possible new strategy. Halim SS; Collins DN; Ramsingh AI AIDS Res Hum Retroviruses; 2000 Oct; 16(15):1551-8. PubMed ID: 11054268 [TBL] [Abstract][Full Text] [Related]
58. Poxvirus vector-based HIV vaccines. Pantaleo G; Esteban M; Jacobs B; Tartaglia J Curr Opin HIV AIDS; 2010 Sep; 5(5):391-6. PubMed ID: 20978379 [TBL] [Abstract][Full Text] [Related]
59. Vehicles for genetic vaccines against human immunodeficiency virus: induction of T cell-mediated immune responses. Hanke T Curr Mol Med; 2001 Mar; 1(1):123-35. PubMed ID: 11899238 [TBL] [Abstract][Full Text] [Related]
60. Role of dendritic cells in HIV-immunotherapy. Van Gulck E; Van Tendeloo VF; Berneman ZN; Vanham G Curr HIV Res; 2010 Jun; 8(4):310-22. PubMed ID: 20353393 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]